IDEAYA Biosciences, Inc.
Moat Score — IDEAYA Biosciences, Inc.
Total Moat Score
8 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | IDEAYA's INQUIRE compound library, HARMONY machine-learning design engine, and DECIPHER dual-CRISPR synthetic lethality library (built with UC San Diego) form a proprietary, repeatable drug-discovery platform, reinforced by in-licensed IP such as darovasertib from Novartis and IDE849 from Hengrui. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a clinical-stage biotech with no manufacturing or commercial scale, IDEAYA has no structural cost advantage; GSK's funding of 80-100% of the WRN and Pol Theta programs reduces IDEAYA's own cash burn but does not reflect a lower-cost operating model. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | IDEAYA has no approved, commercially priced product today, so it currently has no realized pricing power; any future pricing power would depend on darovasertib's eventual approval in the rare-disease uveal melanoma indication. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Drug discovery and clinical development do not generate network effects; one patient's trial enrollment does not make the therapy more valuable to the next patient or physician. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | With no commercial product on the market, there is no customer base to lock in and therefore no switching-cost moat to speak of at this stage. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Uveal melanoma is a rare, orphan-sized indication where only a handful of companies (Immunocore, Aura Biosciences, Novartis) are actively developing targeted therapies, giving darovasertib a narrower competitive field than a typical oncology indication would see. |